Cationic lipids percentage and processing temperature are critical in designing siRNA lipid nanoparticles

Journal of Drug Targeting

Volumn 20, Issue 3, 2012, Pages 281-289

  Zhao, Xiaobin ^a   Liu, Yemin ^a   Song, Jingfeng ^a   Yong, Hong ^a   Li, Leiming ^b   Shen, Yu ^b   Hubbard, Robert D ^b   Kohlbrenner, William E ^b   Zhou, Ji ^a   Cluff, Kevin D ^a   Skoug, John W ^a  

^a Global Pharmaceutical and Analytical Sciences   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Design of experiments; Lipid nanoparticle; SiRNA

Indexed keywords

LIPID NANOPARTICLE; NANOPARTICLE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEMALE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TEMPERATURE;

ANIMALS; FEMALE; HOT TEMPERATURE; LIPIDS; MICE; MICE, SCID; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; PARTICLE SIZE; PHYSICOCHEMICAL PHENOMENA; RNA INTERFERENCE; RNA, SMALL INTERFERING; SURFACE PROPERTIES; TRANSITION TEMPERATURE;

EID: 84863294823     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.645160     Document Type: Article

References (22)

1. Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B, Janke O, Endruschat J, Durieux B, Röder N, Löffler K, Lange C, Fectner M, Möpert K, Fisch G, Dames S, Arnold W, Jochims K, Giese K, Wiedenmann B, Scholz A, Kaufmann J. (2008). Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res, 68, 9788-9798.
2. Bouclier C, Moine L, Hillaireau H, Marsaud V, Connault E, Opolon P, Couvreur P, Fattal E, Renoir JM. (2008). Physicochemical characteristics and preliminary in vivo biological evaluation of nanocapsules loaded with siRNA targeting estrogen receptor alpha. Biomacromolecules, 9, 2881-2890.
3. Caracciolo G, Pozzi D, Caminiti R, Marchini C, Montani M, Amici A, Amenitsch H. (2008). Enhanced transfection efficiency of multicomponent lipoplexes in the regime of optimal membrane charge density. J Phys Chem B, 112, 11298-11304.
4. Davis ME. (2009). The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm, 6, 659-668.
5. Harms J, Wang X, Kim T, Yang X, Rathore AS. (2008). Defining process design space for biotech products: case study of Pichia pastoris fermentation. Biotechnol Prog, 24, 655-662.
6. Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME. (2007). Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA, 104, 5715-5721.
7. Jiang W, Kim BY, Rutka JT, Chan WC. (2008). Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol, 3, 145-150.
8. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, Ambegia E, McClintock K, MacLachlan I. (2009). Confirming the RNAimediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest, 119, 661-673.
9. Kawano K, Onose E, Hattori Y, Maitani Y. (2009). Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal mitoxantrone. Mol Pharm, 6, 98-104.
10. Kirdar AO, Green KD, Rathore AS. (2008). Application of multivariate data analysis for identification and successful resolution of a root cause for a bioprocessing application. Biotechnol Prog, 24, 720-726.
11. Kusumoto K. (2009). Structural features of glutamate-based lipidic materials for small interfering RNA delivery system. J Biomed Mater Res A, 89, 739-750.
12. Lin X, Li L, Wang R, Wilcox D, Zhao X, Song J, Huang X, Hansen TM, Dande P, Wada C, Hubbard RD, Kohlbrenner WM, Fesik SW, Shen Y. (2011). A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors. RNA, 17, 603-612.
13. Mandenius CF, Graumann K, Schultz TW, Premstaller A, Olsson IM, Petiot E, Clemens C, Welin M. (2009). Quality-by-design for biotechnology-related pharmaceuticals. Biotechnol J, 4, 600-609.
14. Rathore AS. (2009). Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol, 27, 546-553.
15. Rini BI, Selk LM, Vogelzang NJ. (1999). Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res, 5, 2766-2772.
16. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, Dames S, Löffler K, Fechtner M, Arnold W, Giese K, Klippel A, Kaufmann J. (2006). A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther, 13, 1222-1234.
17. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, Hafez IM, Dorkin JR, Qin J, Lam K, Rajeev KG, Wong KF, Jeffs LB, Nechev L, Eisenhardt ML, Jayaraman M, Kazem M, Maier MA, Srinivasulu M, Weinstein MJ, Chen Q, Alvarez R, Barros SA, De S, Klimuk SK, Borland T, Kosovrasti V, Cantley WL, Tam YK, Manoharan M, Ciufolini MA, Tracy MA, de Fougerolles A, MacLachlan I, Cullis PR, Madden TD, Hope MJ. (2010). Rational design of cationic lipids for siRNA delivery. Nat Biotechnol, 28, 172-176.
18. Spagnou S, Miller AD, Keller M. (2004). Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry, 43, 13348-13356.
19. Stopeck AT, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC, Gonzalez R. (2001). Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNAliposome complex, in patients with metastatic melanoma. Clin Cancer Res, 7, 2285-2291.
20. Wang L, Koynova R, Parikh H, MacDonald RC. (2006). Transfection activity of binary mixtures of cationic o-substituted phosphatidylcholine derivatives: the hydrophobic core strongly modulates physical properties and DNA delivery efficacy. Biophys J, 91, 3692-3706.
21. Whitehead KA, Langer R, Anderson DG. (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov, 8, 129-138.
22. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Röhl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I. (2006). RNAi-mediated gene silencing in nonhuman primates. Nature, 441, 111-114.